FibroBiologics’ (FBLG) Hold Rating Reiterated at Maxim Group

FibroBiologics (NASDAQ:FBLG)‘s stock had its “hold” rating reaffirmed by stock analysts at Maxim Group in a research note issued on Monday,Benzinga reports.

A number of other research analysts have also recently weighed in on FBLG. Wall Street Zen upgraded shares of FibroBiologics to a “sell” rating in a research report on Saturday, April 4th. D. Boral Capital restated a “hold” rating on shares of FibroBiologics in a research note on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Tuesday, April 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective (up from $4.00) on shares of FibroBiologics in a research report on Thursday, April 16th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $74.00.

FibroBiologics Stock Performance

FBLG stock opened at $1.39 on Monday. The firm has a fifty day moving average price of $3.89 and a 200 day moving average price of $5.44. FibroBiologics has a fifty-two week low of $1.03 and a fifty-two week high of $22.60. The firm has a market cap of $4.87 million, a PE ratio of -0.20 and a beta of 1.16.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.33) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.33). On average, equities analysts predict that FibroBiologics will post -4.41 EPS for the current year.

Insider Activity at FibroBiologics

In other news, CFO Jason Davis acquired 3,500 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average price of $8.20 per share, with a total value of $28,700.00. Following the completion of the acquisition, the chief financial officer owned 3,500 shares of the company’s stock, valued at $28,700. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders acquired 9,574 shares of company stock worth $72,886. 13.00% of the stock is owned by insiders.

Institutional Trading of FibroBiologics

A number of institutional investors and hedge funds have recently bought and sold shares of FBLG. Jane Street Group LLC acquired a new stake in FibroBiologics in the fourth quarter valued at approximately $34,000. Renaissance Technologies LLC grew its stake in FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after buying an additional 171,800 shares during the last quarter. Geode Capital Management LLC increased its position in FibroBiologics by 20.7% during the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after buying an additional 59,813 shares during the period. AMG National Trust Bank purchased a new stake in FibroBiologics in the fourth quarter valued at approximately $31,000. Finally, Yorkville Advisors Global LP acquired a new stake in shares of FibroBiologics in the third quarter valued at approximately $278,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.